N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Sponsor: CSL Behring • ClinicalTrials.gov ID: NCT06617897

Registry updated: 2026-10-13
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (\>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.

Interventions

  • CSL511 Fibrinogen concentrate (human) (Biological)
    CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.
  • Cryoprecipitate (Biological)
    Cryoprecipitate will be administered via IV infusion.

Eligibility criteria

Inclusion Criteria: * • Aged \>= 18 years at the time of providing written informed consent. * • Diagnosis of PMP requiring CRS with HIPEC. * • Bleeding risk: Predicted intraoperative blood loss of \>=2L, assessed within 60 and 100 mins after start of study surgery (assessment made before 2 L of blood is lost) Exclusion Criteria: * • Confirmed or suspected congenital or acquired coagulation disorder or a prothrombotic disorder * • Myocardial infarction, acute coronary syndrome, or stroke within 2 months before study surgery. * • Known history of chronic hepatitis. * • Clopidogrel or ticagrelor administration within 5 days before study surgery. * • Prasugrel administration within 7 days before study surgery. * • Oral factor Xa inhibitor administration within 2 days before study surgery. * • Glycoprotein IIb / IIIa antagonist administration within 24 hours before study surgery. * • Oral direct thrombin inhibitor administration within 3 days before study surgery. * • Vitamin K antagonists within 5 days before study surgery.

Conditions

Acquired Fibrinogen Deficiency

Locations

  • Basingstoke and North Hampshire Hospital — Basingstoke, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record